November 29, 2016 - By Ruchi Gupta
Numis currently has a GBX 267.00 price target on the 56.01M GBP market cap company or 92.09% upside potential. In an analyst report issued to clients and investors on 29 November, Ergomed Plc (LON:ERGO) stock had its “Buy” Rating kept by stock analysts at Numis.
Out of 3 analysts covering Ergomed (LON:ERGO), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 290 is the highest target while GBX 265 is the lowest. The GBX 271 average target is 92.20% above today’s (GBX 141) stock price. Ergomed has been the topic of 15 analyst reports since September 29, 2015 according to StockzIntelligence Inc. N+1 Singer maintained Ergomed PLC (LON:ERGO) on Monday, November 7 with “Buy” rating. The company was maintained on Wednesday, October 21 by Stifel Nicolaus. N+1 Singer maintained the stock with “Buy” rating in Monday, September 26 report. The firm has “Buy” rating by N+1 Singer given on Wednesday, October 21. On Monday, October 17 the stock rating was maintained by Numis Securities with “Buy”. The company was maintained on Friday, October 21 by N+1 Singer. N+1 Singer maintained the stock with “Buy” rating in Tuesday, September 29 report. The firm has “Buy” rating given on Wednesday, December 16 by N+1 Singer. The firm earned “Buy” rating on Tuesday, November 1 by N+1 Singer. As per Tuesday, November 1, the company rating was maintained by Numis Securities.
About 17,833 shares traded hands. Ergomed PLC (LON:ERGO) has declined 8.93% since April 28, 2016 and is downtrending. It has underperformed by 14.19% the S&P500.
Analysts await Entia Biosciences Inc (OTCMKTS:ERGO) to report earnings on December, 29.
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The company has a market cap of 56.01 million GBP. The Firm operates through two divisions: clinical research services , and drug safety and medical information services (DS&MI). It has a 31.24 P/E ratio. It provides a range of clinical trial planning, management and monitoring services.
According to Zacks Investment Research, “Entia Biosciences, Inc. is engaged in the discovery, scientific evaluation and marketing of natural formulations of medical foods, nutraceuticals, cosmetics and other products. Entia Biosciences, Inc. is headquartered in Sherwood, Oregon.”
Entia Biosciences, Inc., incorporated on July 19, 2007, develops pharmaceutical-grade organic compounds, including a foundational compound called ErgoD2. The Firm also develops and markets health-related nutraceuticals and cosmeceuticals. ErgoD2 is a pharmaceutical-grade organic compound created from whole foods that contain the micro-nutrients L-ergothioneine, an amino acid that has a transporter (SLC22A4) in every human being, and vitamin D2. ErgoD2 improves iron homeostasis and mitigates iron-related disorders presenting in anemia, chronic kidney disease and select neurodegenerative diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Ruchi Gupta